Endocrine dysfunction induced by treatment with opioids

DOI Web Site 38 References
  • TABUCHI Yukiko
    Department of Metabolic Medicine, Osaka University Graduate School of Medicine
  • YASUDA Tetsuyuki
    Department of Metabolic Medicine, Osaka University Graduate School of Medicine
  • KITAMURA Tetsuhiro
    Department of Metabolic Medicine, Osaka University Graduate School of Medicine
  • OTSUKI Michio
    Department of Metabolic Medicine, Osaka University Graduate School of Medicine
  • KANETO Hideaki
    Department of Metabolic Medicine, Osaka University Graduate School of Medicine
  • INOUE Takaya
    Department of Anesthesiology and Intensive Care, Osaka University Graduate School of Medicine
  • NAKAE Aya
    Department of Anesthesiology and Intensive Care, Osaka University Graduate School of Medicine
  • MATSUDA Youichi
    Department of Anesthesiology and Intensive Care, Osaka University Graduate School of Medicine
  • UEMATSU Hironobu
    Department of Anesthesiology, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases
  • MASHIMO Takashi
    Department of Anesthesiology and Intensive Care, Osaka University Graduate School of Medicine
  • SHIMOMURA Iichiro
    Department of Metabolic Medicine, Osaka University Graduate School of Medicine
  • SHIBATA Masahiko
    Department of Pain Medicine, Osaka University Graduate School of Medicine

Bibliographic Information

Other Title
  • オピオイドによる内分泌機能異常
  • オピオイド ニ ヨル ナイブンピ キノウ イジョウ

Search this article

Description

Opioids have been widely used for the management of acute and chronic pain, but they present several adverse effects such as fatigue, itching, nausea, and constipation. Recently it has been reported that chronic use of opioids has an influence on the endocrine system in humans. The most common endocrine dysfunction is hypogonadism, leading not only to a decrease in sexual function, but also to impaired physical and psychological conditions such as fatigue, muscle weakness, and depression. On the other hand, it has been reported that adrenal insufficiency and adult growth-hormone deficiency can also occur. These endocrine dysfunctions not only lead to impaired quality of life, metabolic abnormality, and organ damage, but they also may induce lethal conditions. Furthermore, these adverse effects can be avoided by either stopping or decreasing opioid treatment or by undertaking hormone replacement therapy. Taken together, it is very important for pain physicians to consider endocrine dysfunctions during long-term treatment with opioids.

Journal

References(38)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top